Oral analogues of GLP-1: perspectives on glycemic control and cardiorenal risk in patients with type 2 diabetes mellitus
At present, type 2 diabetes mellitus (T2DM) is the leading cause of end-stage kidney disease. The management of T2DM in recent years has moved from a glucocentric approach to a global approach with the priority of introducing treatments that offer renal and cardiovascular protection. In this article...
- Autores:
-
Rico-Fontalvo, Jorge
daza arnedo, rodrigo andres
Vázquez Jiménez, Lourdes Carolina
Rodríguez-Yánez, Tomas
Raad Sarabia, Maria Isabel
TOAPANTA, NÉSTOR
Pérez, Rafael V.
Montejo-Hernández, Juan
Soler, María J.
- Tipo de recurso:
- Fecha de publicación:
- 2024
- Institución:
- Universidad Simón Bolívar
- Repositorio:
- Repositorio Digital USB
- Idioma:
- eng
- OAI Identifier:
- oai:bonga.unisimon.edu.co:20.500.12442/16665
- Acceso en línea:
- https://hdl.handle.net/20.500.12442/16665
http://dx.doi.org/10.24875/NEFRO.M24000021
https://www.nefrologialatinoamericana.com/frame_eng.php?id=120
- Palabra clave:
- Diabetes mellitus
Glucagon-like peptide 1 receptor analogs
Semaglutide
Diabetes Mellitus
Análogos del receptor del péptido similar al glucagón tipo 1
Semaglutida
- Rights
- openAccess
- License
- Attribution-NonCommercial-NoDerivatives 4.0 International